Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Surgery Partners Inc has a consensus price target of $39.92 based on the ratings of 14 analysts. The high is $51 issued by Barclays on August 2, 2023. The low is $28 issued by JP Morgan on December 3, 2024. The 3 most-recent analyst ratings were released by RBC Capital, Macquarie, and JP Morgan on March 25, 2025, March 11, 2025, and December 3, 2024, respectively. With an average price target of $32 between RBC Capital, Macquarie, and JP Morgan, there's an implied 33.61% upside for Surgery Partners Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/25/2025 | Buy Now | 46.14% | RBC Capital | Ben Hendrix60% | $35 → $35 | Reiterates | Outperform → Outperform | Get Alert |
03/11/2025 | Buy Now | 37.79% | Macquarie | Tao Qiu46% | $34 → $33 | Maintains | Outperform | Get Alert |
12/03/2024 | Buy Now | 16.91% | JP Morgan | Lisa Gill59% | $38 → $28 | Maintains | Neutral | Get Alert |
11/20/2024 | Buy Now | 46.14% | RBC Capital | Ben Hendrix60% | $49 → $35 | Maintains | Outperform | Get Alert |
11/19/2024 | Buy Now | 41.96% | Macquarie | Tao Qiu46% | $34 → $34 | Maintains | Outperform | Get Alert |
11/13/2024 | Buy Now | 41.96% | Macquarie | Tao Qiu46% | $35 → $34 | Maintains | Outperform | Get Alert |
11/04/2024 | Buy Now | 46.14% | Macquarie | Tao Qiu46% | $35 → $35 | Maintains | Outperform | Get Alert |
10/14/2024 | Buy Now | 58.66% | UBS | A.J. Rice68% | → $38 | Initiates | → Buy | Get Alert |
10/11/2024 | Buy Now | — | Keybanc | Matthew Gillmor65% | — | Initiates | → Sector Weight | Get Alert |
10/04/2024 | Buy Now | 79.54% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
08/26/2024 | Buy Now | 108.77% | Benchmark | Bill Sutherland62% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
08/20/2024 | Buy Now | 79.54% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
08/19/2024 | Buy Now | 79.54% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
08/07/2024 | Buy Now | 50.31% | Citigroup | Jason Cassorla50% | $38 → $36 | Maintains | Buy | Get Alert |
08/07/2024 | Buy Now | 108.77% | Benchmark | Bill Sutherland62% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
08/07/2024 | Buy Now | 104.59% | RBC Capital | Ben Hendrix60% | $49 → $49 | Reiterates | Outperform → Outperform | Get Alert |
07/10/2024 | Buy Now | 79.54% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
07/09/2024 | Buy Now | 79.54% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
07/02/2024 | Buy Now | 79.54% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
06/28/2024 | Buy Now | 29.44% | Macquarie | Tao Qiu46% | → $31 | Initiates | → Outperform | Get Alert |
05/08/2024 | Buy Now | 58.66% | Citigroup | Jason Cassorla50% | $42 → $38 | Maintains | Buy | Get Alert |
05/01/2024 | Buy Now | 108.77% | Benchmark | Bill Sutherland62% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
04/10/2024 | Buy Now | 79.54% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
03/06/2024 | Buy Now | 46.14% | Barclays | Andrew Mok55% | → $35 | Initiates | → Equal-Weight | Get Alert |
03/05/2024 | Buy Now | 79.54% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Reiterates | Overweight → Overweight | Get Alert |
02/29/2024 | Buy Now | 104.59% | RBC Capital | Ben Hendrix60% | $49 → $49 | Reiterates | Outperform → Outperform | Get Alert |
02/27/2024 | Buy Now | 75.37% | Citigroup | Jason Cassorla50% | $43 → $42 | Maintains | Buy | Get Alert |
02/27/2024 | Buy Now | 79.54% | Cantor Fitzgerald | Sarah James51% | $43 → $43 | Maintains | Overweight | Get Alert |
11/14/2023 | Buy Now | 46.14% | TD Cowen | Gary Taylor59% | $39 → $35 | Upgrade | Market Perform → Outperform | Get Alert |
10/12/2023 | Buy Now | 108.77% | Benchmark | Bill Sutherland62% | → $50 | Reiterates | Buy → Buy | Get Alert |
09/14/2023 | Buy Now | 79.54% | Cantor Fitzgerald | Sarah James51% | → $43 | Reiterates | Overweight → Overweight | Get Alert |
08/02/2023 | Buy Now | 108.77% | Benchmark | Bill Sutherland62% | → $50 | Reiterates | Buy → Buy | Get Alert |
08/02/2023 | Buy Now | 112.94% | Barclays | Marc Solecitto64% | $56 → $51 | Maintains | Overweight | Get Alert |
07/31/2023 | Buy Now | 108.77% | Benchmark | Bill Sutherland62% | → $50 | Reiterates | Buy → Buy | Get Alert |
07/11/2023 | Buy Now | 108.77% | Mizuho | Ann Hynes86% | $48 → $50 | Maintains | Buy | Get Alert |
06/02/2023 | Buy Now | 87.89% | B of A Securities | Kevin Fischbeck67% | $42 → $45 | Upgrade | Neutral → Buy | Get Alert |
05/12/2023 | Buy Now | 100.42% | Mizuho | Ann Hynes86% | → $48 | Initiates | → Buy | Get Alert |
05/02/2023 | Buy Now | 96.24% | RBC Capital | Ben Hendrix60% | → $47 | Reiterates | → Outperform | Get Alert |
05/02/2023 | Buy Now | 108.77% | Benchmark | Bill Sutherland62% | → $50 | Reiterates | → Buy | Get Alert |
05/02/2023 | Buy Now | 96.24% | Citigroup | Jason Cassorla50% | $40 → $47 | Maintains | Buy | Get Alert |
04/21/2023 | Buy Now | 79.54% | Cantor Fitzgerald | Sarah James51% | → $43 | Initiates | → Overweight | Get Alert |
03/06/2023 | Buy Now | 96.24% | Benchmark | Bill Sutherland62% | → $47 | Reiterates | → Buy | Get Alert |
03/02/2023 | Buy Now | 67.01% | JP Morgan | Lisa Gill59% | $45 → $40 | Maintains | Neutral | Get Alert |
01/18/2023 | Buy Now | 133.82% | Barclays | Marc Solecitto64% | $69 → $56 | Maintains | Overweight | Get Alert |
12/05/2022 | Buy Now | 96.24% | Benchmark | Bill Sutherland62% | $60 → $47 | Maintains | Buy | Get Alert |
11/23/2022 | Buy Now | 100.42% | RBC Capital | Ben Hendrix60% | $58 → $48 | Maintains | Outperform | Get Alert |
11/22/2022 | Buy Now | 67.01% | SVB Leerink | Whit Mayo67% | $55 → $40 | Maintains | Outperform | Get Alert |
11/10/2022 | Buy Now | 142.17% | RBC Capital | Ben Hendrix60% | $62 → $58 | Maintains | Outperform | Get Alert |
11/10/2022 | Buy Now | 129.65% | SVB Leerink | Whit Mayo67% | $57 → $55 | Maintains | Outperform | Get Alert |
11/09/2022 | Buy Now | 58.66% | Citigroup | Jason Cassorla50% | $49 → $38 | Maintains | Buy | Get Alert |
08/03/2022 | Buy Now | 158.87% | RBC Capital | Ben Hendrix60% | $65 → $62 | Maintains | Outperform | Get Alert |
06/15/2022 | Buy Now | 50.31% | B of A Securities | Kevin Fischbeck67% | → $36 | Downgrade | Buy → Neutral | Get Alert |
05/04/2022 | Buy Now | 167.22% | Citigroup | Jason Cassorla50% | $61 → $64 | Maintains | Buy | Get Alert |
The latest price target for Surgery Partners (NASDAQ:SGRY) was reported by RBC Capital on March 25, 2025. The analyst firm set a price target for $35.00 expecting SGRY to rise to within 12 months (a possible 46.14% upside). 23 analyst firms have reported ratings in the last year.
The latest analyst rating for Surgery Partners (NASDAQ:SGRY) was provided by RBC Capital, and Surgery Partners reiterated their outperform rating.
The last upgrade for Surgery Partners Inc happened on November 14, 2023 when TD Cowen raised their price target to $35. TD Cowen previously had a market perform for Surgery Partners Inc.
The last downgrade for Surgery Partners Inc happened on June 15, 2022 when B of A Securities changed their price target from N/A to $36 for Surgery Partners Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Surgery Partners, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Surgery Partners was filed on March 25, 2025 so you should expect the next rating to be made available sometime around March 25, 2026.
While ratings are subjective and will change, the latest Surgery Partners (SGRY) rating was a reiterated with a price target of $35.00 to $35.00. The current price Surgery Partners (SGRY) is trading at is $23.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.